Current approaches to drug development have resulted in an 88% failure rate in clinical trials and $151 billion spent every year on research and development. A key factor driving this failure rate is the use of Caco-2 cells (cancer cells) and animal testing, which are an essential part of preclinical trials and yet cannot accurately predict human results.

That’s why Altis developed a next-generation intestinal platform that produces a layer of human intestinal stem and differentiated cells – either of the large or small intestine – that can be used for compound screening, disease modeling, and microbiome research. It can also be used to study many aspects of drug disposition including toxicity, metabolism, drug absorption, and efficacy.

Altis Biosystems Downloads

Characterization of a Novel Human Primary Intestinal Epithelial Monolayer Platform in Response to Cytokine Challenge (Poster) - Brochure

Contact supplier